Cannabis (Cannabis sativa) and its related extracts, such as CBD, continue to command the regulatory spotlight. In response to an FDA call for public comments on the global regulatory status of cannabis and cannabis -related substances, herbal experts and industry leaders have urged the agency not … Read More
The post Cannabis , CBD Should Not Be Schedule I Drugs, Herbal Leaders Urge FDA in Public Comments appeared first on Dagga Magazine.